Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,076Revenue $M1.1Net Margin (%)-880.1Z-Score38.6
Enterprise Value $M1,009EPS $-1.2Operating Margin %-1,081.3F-Score5
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-1,080.1Higher ROA y-yY
Price/Book15.310-y EBITDA Growth Rate %0Quick Ratio10.9Cash flow > EarningsY
Price/Sales2965-y EBITDA Growth Rate %0Current Ratio10.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-40.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-48.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M27.9ROI % (ttm)-59.8Gross Margin Increase y-yN

Gurus Latest Trades with NLNK

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NLNKJean-Marie Eveillard 2014-03-31 Add0.02%$21.38 - $50.4
($33.68)
$ 38.4714%Add 28.35%1,161,805
NLNKJean-Marie Eveillard 2013-09-30 Add0.01%$15.78 - $20.08
($17.83)
$ 38.47116%Add 21.32%778,354
NLNKJean-Marie Eveillard 2013-06-30 Add0.02%$11.27 - $22.56
($15.73)
$ 38.47145%Add 95.04%641,554
NLNKJean-Marie Eveillard 2013-03-31 Buy 0.01%$11.4 - $12.7
($12.08)
$ 38.47218%New holding, 328939 sh.328,939
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NLNK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NLNK - CALLJean-Marie Eveillard 2014-09-3011,7600.040.02
NLNK Jean-Marie Eveillard 2014-09-301,257,6194.510.07-3.78%
Premium Most recent portfolio changes are included for Premium Members only!


NLNK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HENNEMAN JOHN B IIIEVP, CFO 2014-11-25Buy5,000$34.3511.99view
Link Charles J. Jr.Chairman of the Board and CEO 2014-11-10Sell20,000$32.9416.79view
LINK GORDON H JRCFO 2014-10-24Sell2,500$40.39-4.75view
Ramsey William J.Quality Assurance Officer 2014-10-22Sell10,000$40-3.83view
Link Charles J. Jr.Chairman of the Board and CEO 2014-10-22Sell25,000$40.26-4.45view
Ramsey William J.Quality Assurance Officer 2014-10-16Sell5,000$3028.23view
Link Charles J. Jr.Chairman of the Board and CEO 2014-10-06Sell20,000$22.7269.32view
Ramsey William J.Quality Assurance Officer 2014-10-01Sell2,500$23.2565.46view
Link Charles J. Jr.Chairman of the Board and CEO 2014-09-05Sell20,000$25.6849.81view
Ramsey William J.Quality Assurance Officer 2014-09-02Sell2,500$26.445.72view

Press Releases about NLNK :

    Quarterly/Annual Reports about NLNK:

    News about NLNK:

    Articles On GuruFocus.com
    NewLink Genetics Corporation Offers a Risky Way to Generate Income Sep 11 2013 
    Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 

    More From Other Websites
    Analyst: NewLink deal a 'boost' for Ebola vaccine Nov 26 2014
    Merck buys rights to NewLink's experimental Ebola vaccine Nov 24 2014
    Merck Obtains Rights to Ebola Vaccine Nov 24 2014
    Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational... Nov 24 2014
    Merck buys rights to NewLink's experimental Ebola vaccine Nov 24 2014
    Merck to Collaborate With NewLink on Experimental Ebola Vaccine Nov 24 2014
    NEWLINK GENETICS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 24 2014
    Merck, NewLink to collaborate on Ebola vaccine Nov 24 2014
    Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational... Nov 24 2014
    Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational... Nov 24 2014
    NewLink in Talks With Merck on Producing Ebola Vaccine Nov 20 2014
    Ebola-infected Cuban doctor to be flown to Geneva for treatment Nov 19 2014
    NEWLINK GENETICS CORP Financials Nov 19 2014
    Cuban doctor to be flown to Geneva for Ebola care - Swiss Nov 19 2014
    Cuban doctor to be flown to Geneva for Ebola care - Swiss Nov 19 2014
    NEWLINK GENETICS CORP Files SEC form 8-K, Other Events Nov 17 2014
    NewLink Genetics to Participate in the Upcoming Stifel, Jeffries, and Piper Jaffray Healthcare... Nov 17 2014
    NewLink Genetics to Participate in the Upcoming Stifel, Jeffries, and Piper Jaffray Healthcare... Nov 17 2014
    NEWLINK GENETICS CORP Files SEC form 8-K, Other Events Nov 14 2014
    NewLink Genetics Appoints Thomas P. Monath, M.D. to the Position of Chief Scientific and Chief... Nov 14 2014
    NewLink Genetics Appoints Thomas P. Monath, M.D. to the Position of Chief Scientific and Chief... Nov 14 2014
    NEWLINK GENETICS CORP Files SEC form 10-Q, Quarterly Report Nov 10 2014
    NewLink Genetics (NLNK) Highlighted As Today's Perilous Reversal Stock Nov 07 2014
    UPDATE: Stifel Reiterates On NewLink Genetics On Good Risk/Reward Nov 07 2014
    NewLink (NLNK) Stock: Moving Average Crossover Alert Nov 06 2014
    NewLink tops Street 3Q forecasts Nov 06 2014
    NewLink tops Street 3Q forecasts Nov 06 2014
    NEWLINK GENETICS CORP Files SEC form 8-K, Results of Operations and Financial Condition Nov 06 2014
    NewLink Genetics Corporation Reports Third Quarter 2014 Financial Results Nov 06 2014
    NewLink Genetics to Host Its Third Quarter 2014 Earnings Results Conference Call on November 6, 2014 Oct 27 2014
    Tens of thousands expected to get Ebola vaccines from January - WHO Oct 21 2014
    Tens of thousands expected to get Ebola vaccines from January - WHO Oct 21 2014
    NewLink Genetics Announces Exclusive Worldwide Licensing Agreement for Development of NLG919, an IDO... Oct 20 2014
    GSK, NewLink working to bring Ebola vaccines online - WHO Oct 01 2014
    GSK, NewLink working to bring Ebola vaccines online - WHO Oct 01 2014
    Scientists grapple with ethics in rush to release Ebola vaccines Sep 29 2014
    Scientists grapple with ethics in rush to release Ebola vaccines Sep 28 2014
    WHO sees small-scale use of experimental Ebola vaccines in January Sep 26 2014
    WHO sees small-scale use of experimental Ebola vaccines in January Sep 26 2014
    Experimental Ebola drug ZMapp cures 100 percent of lab monkeys Aug 29 2014
    NewLink Genetics to Present Data at the AACR 2014 Annual Meeting Mar 25 2014
    NewLink Genetics Corporation Reports Fourth Quarter and Year End 2013 Financial Results Mar 11 2014
    NewLink Genetics' Independent Review Committee Recommends Study Continuation Without Modification... Mar 07 2014
    NewLink Genetics Appoints Eugene P. Kennedy, M.D., as Vice President for Clinical and Medical... Feb 26 2014
    NewLink Genetics to Present at 2014 Leerink Global Healthcare Conference Feb 11 2014
    NewLink Genetics to Present at the 32nd Annual JP Morgan Healthcare Conference Jan 06 2014
    NewLink Genetics Launches Phase 1 Clinical Trial of Its HyperAcute(TM) Renal Immunotherapy in... Dec 19 2013
    NewLink Genetics Initiates Phase 1 Clinical Trial of NLG919, a Novel Immune Checkpoint Inhibitor for... Dec 10 2013
    / CORRECTION - NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference Dec 05 2013

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK